These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26602775)

  • 1. Reply to the letter to the editor 'How much evidence isn't in evidence-based guidelines?' by Johnson et al.
    Cherny NI; Kloke M; Cervantes A; Pentheroudakis G;
    Ann Oncol; 2016 Mar; 27(3):550-1. PubMed ID: 26602775
    [No Abstract]   [Full Text] [Related]  

  • 2. How much evidence isn't in evidence-based guidelines?
    Johnson MJ; Currow DC
    Ann Oncol; 2016 Jan; 27(1):205. PubMed ID: 26489446
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of dyspnoea in advanced cancer patients: ESMO Clinical Practice Guidelines.
    Kloke M; Cherny N;
    Ann Oncol; 2015 Sep; 26 Suppl 5():v169-73. PubMed ID: 26314777
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to "Letter to the editor: 'Why isn't clinical experience with ouabain more widely accepted?'".
    Blaustein MP
    Am J Physiol Heart Circ Physiol; 2014 Oct; 307(8):H1264-5. PubMed ID: 25320336
    [No Abstract]   [Full Text] [Related]  

  • 5. An unusual cause for severe dyspnea and sudden death in a young man.
    Wolf P; Garvin L; Strong P; Lorey T
    Am J Cardiovasc Pathol; 1995; 5(1):89-94. PubMed ID: 8838160
    [No Abstract]   [Full Text] [Related]  

  • 6. Progressive dyspnea in a 39-year-old housewife.
    Steinbrecher UP; Wang NS
    Can Med Assoc J; 1980 Mar; 122(6):648-53. PubMed ID: 7363228
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to the Letter to the Editor by Hendriks et al.
    Eberhardt WE; Mitchell A; Rami-Porta R
    J Thorac Oncol; 2016 Mar; 11(3):e43-4. PubMed ID: 26922925
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to the Letter to the Editor From Zhou et al.
    Dagogo-Jack I; Mino-Kenudson M
    J Thorac Oncol; 2020 Aug; 15(8):e136-e137. PubMed ID: 32718538
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to the Letter to the Editor by C. Nicolazzo et al.: "Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy".
    Alama A; Coco S; Vanni I; Grossi F
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28629197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reply to letter to the editor.
    Zhang Z
    Thorac Cardiovasc Surg; 2014 Mar; 62(2):118-9. PubMed ID: 24783250
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to the Letter to the Editor From He Y et al.
    Okubo Y; Yatabe Y
    J Thorac Oncol; 2023 May; 18(5):e46-e48. PubMed ID: 37087120
    [No Abstract]   [Full Text] [Related]  

  • 12. A patient with HIV, dyspnea, and multiple pulmonary nodules: pulmonary Kaposi sarcoma.
    Joshi M; Markelova N; Palacio D; Schapira RM
    Chest; 2006 Dec; 130(6):1924-8. PubMed ID: 17167017
    [No Abstract]   [Full Text] [Related]  

  • 13. Authors reply to letter to the editor by Dr Degens et al.
    Bommart S; Pujol JL; Coffy A; Daurès JP; Roch B
    Lung Cancer; 2021 Mar; 153():185. PubMed ID: 33461818
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to the letter to the editor 'Ablative therapies for lung metastases: a need to acknowledge the efficacy and toxicity of stereotactic ablative body radiotherapy' by Siva et al.
    de Baère T; Aupérin A; Deschamps F; Chevallier P; Gaubert Y; Boige V; Fonck M; Escudier B; Palussiére J
    Ann Oncol; 2015 Oct; 26(10):2196-7. PubMed ID: 26193885
    [No Abstract]   [Full Text] [Related]  

  • 15. Pulmonary masses in a patient with dyspnea: Apply Occam's razor or Hickam's dictum?
    Leung N; Grogan M; Johnson GB; Klecka ME; Dispenzeiri A
    Am J Hematol; 2015 May; 90(5):462-5. PubMed ID: 25297538
    [No Abstract]   [Full Text] [Related]  

  • 16. Gradually Enlarging Crazy-paving Appearance.
    Kunimasa K; Tachihara M; Terashita T; Nishimura Y
    Intern Med; 2015; 54(21):2791-2. PubMed ID: 26521917
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to the letter to the editor 'Flaws in the trial design of IFCT-0802' by Gyawali et al.
    Pujol JL; Morin F; Zalcman G;
    Ann Oncol; 2015 Oct; 26(10):2199. PubMed ID: 26254441
    [No Abstract]   [Full Text] [Related]  

  • 18. reply to the letter to the editor 'Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced non-small-cell lung cancer enrolled in ARCHER-1042 trial' by Ceccarelli et al.
    Lacouture ME;
    Ann Oncol; 2016 Nov; 27(11):2138-2139. PubMed ID: 27664149
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply to the letter to the editor 'Prevalence of rare EGFR mutations in non-small cell lung cancer: a multicenter study on 3856 Polish Caucasian patients' by Krawczyk et al.
    Beau-Faller M; Cadranel J
    Ann Oncol; 2016 Feb; 27(2):359-60. PubMed ID: 26658890
    [No Abstract]   [Full Text] [Related]  

  • 20. Letter to the editor: "Why isn't clinical experience with ouabain more widely accepted?".
    Fürstenwerth H
    Am J Physiol Heart Circ Physiol; 2014 Oct; 307(8):H1262-3. PubMed ID: 25320335
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.